Liquidia: Yutrepia's PAH Franchise Has Room To Grow
Liquidia retained the right to market YUTREPIA for PAH under its settlement with United Therapeutics. The settlement limits the drug’s potential in PH-ILD, while YUTREPIA is already generating cash and can still be sold to PAH patients and patients already using it.
Why it matters — Paid PAH starts will indicate how much of the lost PH-ILD growth Liquidia can replace.